{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:41:17Z","timestamp":1789094477266,"version":"build-2803163510"},"reference-count":228,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,3,1]]},"DOI":"10.1093\/jac\/dki473","type":"journal-article","created":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T18:37:50Z","timestamp":1138819070000},"page":"384-410","source":"Crossref","is-referenced-by-count":144,"title":["Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?"],"prefix":"10.1093","volume":"57","author":[{"given":"C.","family":"Charlier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ribaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dromer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. W.","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,1,31]]},"reference":[{"key":"key\n\t\t\t\t20171010171220_B1","doi-asserted-by":"crossref","unstructured":"Richardson K. The discovery and profile of fluconazole. J Chemother1990; 2: 51\u20134.","DOI":"10.1080\/1120009X.1990.11738981"},{"key":"key\n\t\t\t\t20171010171220_B2","doi-asserted-by":"crossref","unstructured":"Richardson K, Brammer KW, Marriott MS et al. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother1985; 27: 832\u20135.","DOI":"10.1128\/AAC.27.5.832"},{"key":"key\n\t\t\t\t20171010171220_B3","doi-asserted-by":"crossref","unstructured":"Van't Wout JW, Mattie H, van Furth R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother1988; 21: 665\u201372.","DOI":"10.1093\/jac\/21.5.665"},{"key":"key\n\t\t\t\t20171010171220_B4","doi-asserted-by":"crossref","unstructured":"Van\u2019t Wout JW, de Graeff-Meeder ER, Paul LC et al. Treatment of two cases of cryptococcal meningitis with fluconazole. Scand J Infect Dis1988; 20: 193\u20138.","DOI":"10.3109\/00365548809032437"},{"key":"key\n\t\t\t\t20171010171220_B5","doi-asserted-by":"crossref","unstructured":"Tucker RM, Williams PL, Arathoon EG et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother1988; 32: 369\u201373.","DOI":"10.1128\/AAC.32.3.369"},{"key":"key\n\t\t\t\t20171010171220_B6","doi-asserted-by":"crossref","unstructured":"Byrne WR, Wajszczuk CP. Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B. Ann Intern Med1988; 108: 384\u20135.","DOI":"10.7326\/0003-4819-108-3-384"},{"key":"key\n\t\t\t\t20171010171220_B7","doi-asserted-by":"crossref","unstructured":"Hughes CE, Beggs WH. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother1987; 19: 171\u20134.","DOI":"10.1093\/jac\/19.2.171"},{"key":"key\n\t\t\t\t20171010171220_B8","doi-asserted-by":"crossref","unstructured":"Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet1997; 33: 52\u201377.","DOI":"10.2165\/00003088-199733010-00005"},{"key":"key\n\t\t\t\t20171010171220_B9","doi-asserted-by":"crossref","unstructured":"Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis1994; 13: 325\u20139.","DOI":"10.1007\/BF01974613"},{"key":"key\n\t\t\t\t20171010171220_B10","doi-asserted-by":"crossref","unstructured":"Schwarze R, Penk A, Pittrow L. Administration of fluconazole in children below 1 year of age. Mycoses1999; 42: 3\u201316.","DOI":"10.1046\/j.1439-0507.1999.00260.x"},{"key":"key\n\t\t\t\t20171010171220_B11","unstructured":"Schwarze R, Penk A, Pittrow L. Treatment of candidal infections with fluconazole in neonates and infants. Eur J Med Res2000; 5: 203\u20138."},{"key":"key\n\t\t\t\t20171010171220_B12","doi-asserted-by":"crossref","unstructured":"Thaler F, Bernard B, Tod M et al. Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob Agents Chemother1995; 5: 1154\u20136.","DOI":"10.1128\/AAC.39.5.1154"},{"key":"key\n\t\t\t\t20171010171220_B13","doi-asserted-by":"crossref","unstructured":"Bozzette SA, Gordon RL, Yen A et al. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report. Clin Infect Dis1992; 4: 701\u20133.","DOI":"10.1093\/clind\/15.4.701"},{"key":"key\n\t\t\t\t20171010171220_B14","doi-asserted-by":"crossref","unstructured":"Debruyne D, Ryckelynck JP, Moulin M et al. Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet1990; 18: 491\u20138.","DOI":"10.2165\/00003088-199018060-00006"},{"key":"key\n\t\t\t\t20171010171220_B15","doi-asserted-by":"crossref","unstructured":"Tod M, Lortholary O, Padoin C et al. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect1997; 3: 143\u20134.","DOI":"10.1111\/j.1469-0691.1997.tb00269.x"},{"key":"key\n\t\t\t\t20171010171220_B16","doi-asserted-by":"crossref","unstructured":"Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica1994; 3: 147\u201356.","DOI":"10.1159\/000310473"},{"key":"key\n\t\t\t\t20171010171220_B17","doi-asserted-by":"crossref","unstructured":"Fasano C, O'Keefe J, Gibbs D. Fluconazole treatment of children with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis1994; 13: 344\u20137.","DOI":"10.1007\/BF01974617"},{"key":"key\n\t\t\t\t20171010171220_B18","doi-asserted-by":"crossref","unstructured":"Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet1997; 72: 253\u20136.","DOI":"10.1002\/(SICI)1096-8628(19971031)72:3<253::AID-AJMG1>3.0.CO;2-S"},{"key":"key\n\t\t\t\t20171010171220_B19","doi-asserted-by":"crossref","unstructured":"Buijk SL, Gyssens IC, Mouton JW et al. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med2001; 27: 115\u201321.","DOI":"10.1007\/s001340000771"},{"key":"key\n\t\t\t\t20171010171220_B20","doi-asserted-by":"crossref","unstructured":"El-Yazigi A, Ellis M, Ernst P et al. Pharmacokinetics of oral fluconazole when used for prophylaxis in bone marrow transplant recipients. Antimicrob Agents Chemother1997; 41: 914\u201317.","DOI":"10.1128\/AAC.41.5.914"},{"key":"key\n\t\t\t\t20171010171220_B21","doi-asserted-by":"crossref","unstructured":"Finch CK, Green CA, Self TH. Fluconazole-carbamazepine interaction. South Med J2002; 95: 1099\u2013100.","DOI":"10.1097\/00007611-200295090-00035"},{"key":"key\n\t\t\t\t20171010171220_B22","doi-asserted-by":"crossref","unstructured":"Tucker RM, Denning DW, Hanson RH et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis1992; 14: 165\u201374.","DOI":"10.1093\/clinids\/14.1.165"},{"key":"key\n\t\t\t\t20171010171220_B23","unstructured":"Stockley IH. Stockley's Drug Interactions: A Source Book of Interactions, Their Mechanisms, Clinical Importance and Management, 6th edn. London, UK: Pharmaceutical Press, 2002."},{"key":"key\n\t\t\t\t20171010171220_B24","doi-asserted-by":"crossref","unstructured":"von Moltke LL, Greenblatt DJ, Duan SX et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol1996; 16: 104\u201312.","DOI":"10.1097\/00004714-199604000-00002"},{"key":"key\n\t\t\t\t20171010171220_B25","unstructured":"Brockmeyer NH, Tillmann I, Mertins L et al. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res1997; 2: 377\u201383."},{"key":"key\n\t\t\t\t20171010171220_B26","doi-asserted-by":"crossref","unstructured":"van Burik JA, Leisenring W, Myerson D et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine1998; 77: 246\u201354.","DOI":"10.1097\/00005792-199807000-00003"},{"key":"key\n\t\t\t\t20171010171220_B27","doi-asserted-by":"crossref","unstructured":"Wingard JR. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis2002; 34: 1386\u201390.","DOI":"10.1086\/340263"},{"key":"key\n\t\t\t\t20171010171220_B28","doi-asserted-by":"crossref","unstructured":"Garbino J, Lew DP, Romand JA et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med2002; 28: 1708\u201317.","DOI":"10.1007\/s00134-002-1540-y"},{"key":"key\n\t\t\t\t20171010171220_B29","doi-asserted-by":"crossref","unstructured":"Gearhart MO. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother1994; 28: 1177\u201381.","DOI":"10.1177\/106002809402801009"},{"key":"key\n\t\t\t\t20171010171220_B30","doi-asserted-by":"crossref","unstructured":"Crerar-Gilbert A, Boots R, Fraenkel D et al. Survival following fulminant hepatic failure from fluconazole induced hepatitis. Anaesth Intensive Care1999; 27: 650\u20132.","DOI":"10.1177\/0310057X9902700616"},{"key":"key\n\t\t\t\t20171010171220_B31","doi-asserted-by":"crossref","unstructured":"Pappas PG, Kauffman CA, Perfect J et al. Alopecia associated with fluconazole therapy. Ann Intern Med1995; 123: 354\u20137.","DOI":"10.7326\/0003-4819-123-5-199509010-00006"},{"key":"key\n\t\t\t\t20171010171220_B32","doi-asserted-by":"crossref","unstructured":"Stevens DA, Diaz M, Negroni R et al. Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group. Chemotherapy1997; 5: 371\u20137.","DOI":"10.1159\/000239592"},{"key":"key\n\t\t\t\t20171010171220_B33","doi-asserted-by":"crossref","unstructured":"Anaissie EJ, Kontoyiannis DP, Huls C et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis1995; 172: 599\u2013602.","DOI":"10.1093\/infdis\/172.2.599"},{"key":"key\n\t\t\t\t20171010171220_B34","doi-asserted-by":"crossref","unstructured":"Gussenhoven MJ, Haak A, Peereboom-Wynia JD et al. Stevens-Johnson syndrome after fluconazole. Lancet1991; 338: 120.","DOI":"10.1016\/0140-6736(91)90112-3"},{"key":"key\n\t\t\t\t20171010171220_B35","doi-asserted-by":"crossref","unstructured":"Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother1999; 43: 1955\u201360.","DOI":"10.1128\/AAC.43.8.1955"},{"key":"key\n\t\t\t\t20171010171220_B36","doi-asserted-by":"crossref","unstructured":"Koks CH, Crommentuyn KM, Hoetelmans RM et al. Can fluconazole concentrations in saliva be used for therapeutic drug monitoring? Ther Drug Monit2001; 4: 449\u201353.","DOI":"10.1097\/00007691-200108000-00022"},{"key":"key\n\t\t\t\t20171010171220_B37","doi-asserted-by":"crossref","unstructured":"Louie A, Drusano GL, Banerjee P et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother1998; 42: 1105\u20139.","DOI":"10.1128\/AAC.42.5.1105"},{"key":"key\n\t\t\t\t20171010171220_B38","doi-asserted-by":"crossref","unstructured":"Pittrow L, Penk A. Plasma and tissue concentrations of fluconazole and their correlation to breakpoints. Mycoses1997; 40: 25\u201332.","DOI":"10.1111\/j.1439-0507.1997.tb00167.x"},{"key":"key\n\t\t\t\t20171010171220_B39","doi-asserted-by":"crossref","unstructured":"Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis1997; 24: 235\u201347.","DOI":"10.1093\/clinids\/24.2.235"},{"key":"key\n\t\t\t\t20171010171220_B40","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. International Fungal Surveillance Participant Group. Clin Microbiol Infect2004; 10 Suppl 1: 11\u201323.","DOI":"10.1111\/j.1470-9465.2004.t01-1-00844.x"},{"key":"key\n\t\t\t\t20171010171220_B41","doi-asserted-by":"crossref","unstructured":"Tortorano AM, Rigoni AL, Biraghi E et al. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother2003; 52: 679\u201382.","DOI":"10.1093\/jac\/dkg393"},{"key":"key\n\t\t\t\t20171010171220_B42","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Messer SA, Boyken L et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol2004; 42: 3142\u20136.","DOI":"10.1128\/JCM.42.7.3142-3146.2004"},{"key":"key\n\t\t\t\t20171010171220_B43","doi-asserted-by":"crossref","unstructured":"Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis1993; 16: 677\u201388.","DOI":"10.1093\/clind\/16.5.677"},{"key":"key\n\t\t\t\t20171010171220_B44","doi-asserted-by":"crossref","unstructured":"Singh N, Wagener MM, Marino IR et al. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation2002; 73: 63\u20137.","DOI":"10.1097\/00007890-200201150-00011"},{"key":"key\n\t\t\t\t20171010171220_B45","doi-asserted-by":"crossref","unstructured":"Fung JJ. Fungal infection in liver transplantation. Transplant Infect Dis2002; 4: 18\u201323.","DOI":"10.1034\/j.1399-3062.4.s3.3.x"},{"key":"key\n\t\t\t\t20171010171220_B46","doi-asserted-by":"crossref","unstructured":"Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med1999; 131: 729\u201337.","DOI":"10.7326\/0003-4819-131-10-199911160-00003"},{"key":"key\n\t\t\t\t20171010171220_B47","doi-asserted-by":"crossref","unstructured":"Gladdy RA, Richardson SE, Davies HD et al. Candida infection in pediatric liver transplant recipients. Liver Transpl Surg1999; 5: 16\u201324.","DOI":"10.1002\/lt.500050105"},{"key":"key\n\t\t\t\t20171010171220_B48","doi-asserted-by":"crossref","unstructured":"Castaldo P, Stratta RJ, Wood RP et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg1991; 126: 149\u201356.","DOI":"10.1001\/archsurg.1991.01410260033005"},{"key":"key\n\t\t\t\t20171010171220_B49","doi-asserted-by":"crossref","unstructured":"Husain S, Tollemar J, Dominguez EA et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation2003; 75: 2023\u20139.","DOI":"10.1097\/01.TP.0000065178.93741.72"},{"key":"key\n\t\t\t\t20171010171220_B50","doi-asserted-by":"crossref","unstructured":"George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med1997; 103: 106\u201313.","DOI":"10.1016\/S0002-9343(97)80021-6"},{"key":"key\n\t\t\t\t20171010171220_B51","doi-asserted-by":"crossref","unstructured":"Dockrell DH, Mendez JC, Jones M et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation1999; 67: 399\u2013403.","DOI":"10.1097\/00007890-199902150-00010"},{"key":"key\n\t\t\t\t20171010171220_B52","unstructured":"Tollemar J, Ericzon BG, Barkholt L et al. Risk factors for deep Candida infections in liver transplant recipients. Transplant Proc1990; 22: 1826\u20137."},{"key":"key\n\t\t\t\t20171010171220_B53","doi-asserted-by":"crossref","unstructured":"Lumbreras C, Cuervas-Mons V, Jara P et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis1996; 174: 583\u20138.","DOI":"10.1093\/infdis\/174.3.583"},{"key":"key\n\t\t\t\t20171010171220_B54","doi-asserted-by":"crossref","unstructured":"Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous\/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation2002; 74: 688\u201395.","DOI":"10.1097\/00007890-200209150-00017"},{"key":"key\n\t\t\t\t20171010171220_B55","unstructured":"Tortorano AM, Viviani MA, Pagano A et al. Candida colonization in orthotopic liver tranplantation: fuconazole versus oral amphoericin B. J Mycol Med1995; 5: 21\u20134."},{"key":"key\n\t\t\t\t20171010171220_B56","doi-asserted-by":"crossref","unstructured":"Kung N, Fisher N, Gunson B et al. Fluconazole prophylaxis for high-risk liver transplant recipients. Lancet1995; 345: 1234\u20135.","DOI":"10.1016\/S0140-6736(95)92014-5"},{"key":"key\n\t\t\t\t20171010171220_B57","doi-asserted-by":"crossref","unstructured":"Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis2004; 38: 161\u201389.","DOI":"10.1086\/380796"},{"key":"key\n\t\t\t\t20171010171220_B58","doi-asserted-by":"crossref","unstructured":"Paya CV. Prevention of fungal infection in transplantation. Transpl Infect Dis2002; 4: S46\u201351.","DOI":"10.1034\/j.1399-3062.4.s3.7.x"},{"key":"key\n\t\t\t\t20171010171220_B59","doi-asserted-by":"crossref","unstructured":"Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev1997; 10: 477\u2013504.","DOI":"10.1128\/CMR.10.3.477"},{"key":"key\n\t\t\t\t20171010171220_B60","unstructured":"Benedetti E, Gruessner AC, Troppmann C et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg1996; 183: 307\u201316."},{"key":"key\n\t\t\t\t20171010171220_B61","doi-asserted-by":"crossref","unstructured":"Lumbreras C, Fernandez I, Velosa J et al. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis1995; 20: 514\u201320.","DOI":"10.1093\/clinids\/20.3.514"},{"key":"key\n\t\t\t\t20171010171220_B62","doi-asserted-by":"crossref","unstructured":"Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis1999; 1: 229\u201336.","DOI":"10.1034\/j.1399-3062.1999.010402.x"},{"key":"key\n\t\t\t\t20171010171220_B63","unstructured":"Kusne S, Furukawa H, Abu-Elmagd K et al. Infectious complications after small bowel transplantation in adults: an update. Transplant Proc1996; 28: 2761\u20132."},{"key":"key\n\t\t\t\t20171010171220_B64","unstructured":"Paterson DL, Ndirangu M, Kwak EJ et al. Opportunistic infections in solid-organ transplant recipients pre-treated with alumetuzumab. In: Abstracts of the Forty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract K-1427, p. 357. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010171220_B65","doi-asserted-by":"crossref","unstructured":"Kramer MR, Marshall SE, Starnes VA et al. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med1993; 153: 2010\u20136.","DOI":"10.1001\/archinte.1993.00410170090009"},{"key":"key\n\t\t\t\t20171010171220_B66","doi-asserted-by":"crossref","unstructured":"Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis1991; 164: 731\u201340.","DOI":"10.1093\/infdis\/164.4.731"},{"key":"key\n\t\t\t\t20171010171220_B67","doi-asserted-by":"crossref","unstructured":"Dykewicz CA, Centers for Disease Control and Prevention (U.S.); Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis2001; 33: 139\u201344.","DOI":"10.1086\/321805"},{"key":"key\n\t\t\t\t20171010171220_B68","doi-asserted-by":"crossref","unstructured":"Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis1994; 18: 273\u201381.","DOI":"10.1093\/clinids\/18.3.273"},{"key":"key\n\t\t\t\t20171010171220_B69","doi-asserted-by":"crossref","unstructured":"Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med1992; 326: 845\u201351.","DOI":"10.1056\/NEJM199203263261301"},{"key":"key\n\t\t\t\t20171010171220_B70","doi-asserted-by":"crossref","unstructured":"Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study. J Infect Dis1995; 171: 1545\u201352.","DOI":"10.1093\/infdis\/171.6.1545"},{"key":"key\n\t\t\t\t20171010171220_B71","doi-asserted-by":"crossref","unstructured":"Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood2000; 96: 2055\u201361.","DOI":"10.1182\/blood.V96.6.2055"},{"key":"key\n\t\t\t\t20171010171220_B72","unstructured":"Alangaden G, Chandrasekar PH, Bailey E et al. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. Bone Marrow Transplant1994; 14: 919\u201324."},{"key":"key\n\t\t\t\t20171010171220_B73","doi-asserted-by":"crossref","unstructured":"Wolff SN, Fay J, Stevens D et al. Fluconazole versus low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant2000; 25: 853\u20139.","DOI":"10.1038\/sj.bmt.1702233"},{"key":"key\n\t\t\t\t20171010171220_B74","unstructured":"Annaloro C, Oriana A, Tagliaferri E et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica1995; 80: 512\u201317."},{"key":"key\n\t\t\t\t20171010171220_B75","doi-asserted-by":"crossref","unstructured":"Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med2003; 138: 705\u201313.","DOI":"10.7326\/0003-4819-138-9-200305060-00006"},{"key":"key\n\t\t\t\t20171010171220_B76","doi-asserted-by":"crossref","unstructured":"Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood2004; 103: 1527\u201333.","DOI":"10.1182\/blood-2003-08-2644"},{"key":"key\n\t\t\t\t20171010171220_B77","doi-asserted-by":"crossref","unstructured":"MacMillan ML, Goodman JL, DeFor TE et al. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med2002; 112: 369\u201379.","DOI":"10.1016\/S0002-9343(01)01127-5"},{"key":"key\n\t\t\t\t20171010171220_B78","doi-asserted-by":"crossref","unstructured":"Marr KA, Seidel K, White TC et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis2000; 181: 309\u201316.","DOI":"10.1086\/315193"},{"key":"key\n\t\t\t\t20171010171220_B79","doi-asserted-by":"crossref","unstructured":"van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis2004; 39: 1407\u201316.","DOI":"10.1086\/422312"},{"key":"key\n\t\t\t\t20171010171220_B80","doi-asserted-by":"crossref","unstructured":"Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol2000; 110: 273\u201384.","DOI":"10.1046\/j.1365-2141.2000.02014.x"},{"key":"key\n\t\t\t\t20171010171220_B81","doi-asserted-by":"crossref","unstructured":"Laverdiere M, Rotstein C, Bow EJ et al. Impact of fluconazole prophylaxis on fungal colonizatin and infection rates in neutropenic patients. The Canadian Fluconazole Study. J. Animicrob Chemother2000; 46: 1001\u20138.","DOI":"10.1093\/jac\/46.6.1001"},{"key":"key\n\t\t\t\t20171010171220_B82","doi-asserted-by":"crossref","unstructured":"Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med1993; 118: 495\u2013503.","DOI":"10.7326\/0003-4819-118-7-199304010-00003"},{"key":"key\n\t\t\t\t20171010171220_B83","doi-asserted-by":"crossref","unstructured":"Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. Chemotherapy1994; 40: 136\u201343.","DOI":"10.1159\/000239184"},{"key":"key\n\t\t\t\t20171010171220_B84","doi-asserted-by":"crossref","unstructured":"Rotstein C, Bow EJ, Laverdiere M et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis1999; 28: 331\u201340.","DOI":"10.1086\/515128"},{"key":"key\n\t\t\t\t20171010171220_B85","doi-asserted-by":"crossref","unstructured":"Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J1997; 71: 284\u20136.","DOI":"10.1136\/pgmj.71.835.284"},{"key":"key\n\t\t\t\t20171010171220_B86","doi-asserted-by":"crossref","unstructured":"Kern W, Behre G, Rudolf T et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer1998; 83: 291\u2013301.","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<291::AID-CNCR13>3.0.CO;2-O"},{"key":"key\n\t\t\t\t20171010171220_B87","doi-asserted-by":"crossref","unstructured":"Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis1995; 172: 1035\u201341.","DOI":"10.1093\/infdis\/172.4.1035"},{"key":"key\n\t\t\t\t20171010171220_B88","doi-asserted-by":"crossref","unstructured":"Egger T, Gratwohl A, Tichelli A et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Support Care Cancer1995; 3: 139\u201346.","DOI":"10.1007\/BF00365855"},{"key":"key\n\t\t\t\t20171010171220_B89","doi-asserted-by":"crossref","unstructured":"Morgenstern GR, Prentice AG, Prentice H et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol1999; 105: 901\u201311.","DOI":"10.1046\/j.1365-2141.1999.01465.x"},{"key":"key\n\t\t\t\t20171010171220_B90","doi-asserted-by":"crossref","unstructured":"Ellis ME, Clink H, Ernst P et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis1994; 13: 3\u201311.","DOI":"10.1007\/BF02026116"},{"key":"key\n\t\t\t\t20171010171220_B91","doi-asserted-by":"crossref","unstructured":"Philpott-Howard JN, Wade JJ, Mufti GJ et al. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother1993; 31: 973\u201384.","DOI":"10.1093\/jac\/31.6.973"},{"key":"key\n\t\t\t\t20171010171220_B92","doi-asserted-by":"crossref","unstructured":"Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur J Clin Microbiol Infect Dis1994; 13: 330\u20137.","DOI":"10.1007\/BF01974614"},{"key":"key\n\t\t\t\t20171010171220_B93","doi-asserted-by":"crossref","unstructured":"Menichetti F, Del Favero A, Martino P et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med1994; 120: 913\u201318.","DOI":"10.7326\/0003-4819-120-11-199406010-00003"},{"key":"key\n\t\t\t\t20171010171220_B94","doi-asserted-by":"crossref","unstructured":"Akiyama H, Mori S, Tanikawa S et al. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses1996; 36: 373\u20138.","DOI":"10.1111\/j.1439-0507.1993.tb00725.x"},{"key":"key\n\t\t\t\t20171010171220_B95","doi-asserted-by":"crossref","unstructured":"Meunier F, Aoun M, Janssens M et al. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole versus oral amphotericin B. Drug Invest1991; 3: 258\u201365.","DOI":"10.1007\/BF03259575"},{"key":"key\n\t\t\t\t20171010171220_B96","doi-asserted-by":"crossref","unstructured":"Rozenberg-Arska M, Dekker AW, Branger J et al. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother1991; 27: 369\u201376.","DOI":"10.1093\/jac\/27.3.369"},{"key":"key\n\t\t\t\t20171010171220_B97","doi-asserted-by":"crossref","unstructured":"Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Haematol Blood Transfus1990; 33: 546\u201350.","DOI":"10.1007\/978-3-642-74643-7_97"},{"key":"key\n\t\t\t\t20171010171220_B98","doi-asserted-by":"crossref","unstructured":"Bodey GP, Anaissie EJ, Elting LS et al. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer1994; 73: 2099\u2013106.","DOI":"10.1002\/1097-0142(19940415)73:8<2099::AID-CNCR2820730814>3.0.CO;2-N"},{"key":"key\n\t\t\t\t20171010171220_B99","doi-asserted-by":"crossref","unstructured":"Kanda Y, Yamamoto R, Chizuka A et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer2000; 89: 1611\u201325.","DOI":"10.1002\/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B"},{"key":"key\n\t\t\t\t20171010171220_B100","doi-asserted-by":"crossref","unstructured":"Bow EJ, Laverdiere M, Lussier N et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer2002; 94: 3230\u201346.","DOI":"10.1002\/cncr.10610"},{"key":"key\n\t\t\t\t20171010171220_B101","doi-asserted-by":"crossref","unstructured":"Viscoli C, Paesmans M, Sanz M et al. Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis2001; 32: 1532\u20137.","DOI":"10.1086\/320514"},{"key":"key\n\t\t\t\t20171010171220_B102","doi-asserted-by":"crossref","unstructured":"Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis2002; 34: 730\u201351.","DOI":"10.1086\/339215"},{"key":"key\n\t\t\t\t20171010171220_B103","doi-asserted-by":"crossref","unstructured":"Cornely OA, Bohme A, Buchheidt D et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors\u2014guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol2003; 82 Suppl 2: 186\u2013200.","DOI":"10.1007\/s00277-003-0773-3"},{"key":"key\n\t\t\t\t20171010171220_B104","doi-asserted-by":"crossref","unstructured":"McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980\u20131997. Clin Infect Dis2001; 33: 641\u20137.","DOI":"10.1086\/322606"},{"key":"key\n\t\t\t\t20171010171220_B105","doi-asserted-by":"crossref","unstructured":"Kibbler CC, Seaton S, Barnes RA et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect2003; 54: 18\u201324.","DOI":"10.1016\/S0195-6701(03)00085-9"},{"key":"key\n\t\t\t\t20171010171220_B106","doi-asserted-by":"crossref","unstructured":"Marchetti O, Bille J, Fluckiger U et al. Fungal Infection Network of Switzerland. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis2004; 38: 311\u201320.","DOI":"10.1086\/380637"},{"key":"key\n\t\t\t\t20171010171220_B107","doi-asserted-by":"crossref","unstructured":"Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis2003; 37: 1172\u20137.","DOI":"10.1086\/378745"},{"key":"key\n\t\t\t\t20171010171220_B108","doi-asserted-by":"crossref","unstructured":"Ibanez-Nolla J, Nolla-Salas M, Leon MA et al. Early diagnosis of candidiasis in nonneutropenic critically ill patients. J Infect2004; 48: 181\u201392.","DOI":"10.1016\/S0163-4453(03)00120-8"},{"key":"key\n\t\t\t\t20171010171220_B109","doi-asserted-by":"crossref","unstructured":"Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis2001; 33: 177\u201386.","DOI":"10.1086\/321811"},{"key":"key\n\t\t\t\t20171010171220_B110","doi-asserted-by":"crossref","unstructured":"Pittet D, Monod M, Suter PM et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg1994; 220: 751\u20138.","DOI":"10.1097\/00000658-199412000-00008"},{"key":"key\n\t\t\t\t20171010171220_B111","doi-asserted-by":"crossref","unstructured":"Sendid B, Poirot JL, Tabouret M et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol2002; 51: 433\u201342.","DOI":"10.1099\/0022-1317-51-5-433"},{"key":"key\n\t\t\t\t20171010171220_B112","doi-asserted-by":"crossref","unstructured":"Bar W, Hecker H. Diagnosis of systemic Candida infections in patients of the intensive care unit. Significance of serum antigens and antibodies. Mycoses2002; 45: 22\u20138.","DOI":"10.1046\/j.1439-0507.2002.00709.x"},{"key":"key\n\t\t\t\t20171010171220_B113","doi-asserted-by":"crossref","unstructured":"Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis2004; 39: S185\u201392.","DOI":"10.1086\/421955"},{"key":"key\n\t\t\t\t20171010171220_B114","doi-asserted-by":"crossref","unstructured":"Sypula WT, Kale-Pradhan PB. Therapeutic dilemma of fluconazole prophylaxis in intensive care. Ann Pharmacother2002; 36: 155\u20139.","DOI":"10.1345\/aph.1A078"},{"key":"key\n\t\t\t\t20171010171220_B115","doi-asserted-by":"crossref","unstructured":"Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg2001; 233: 542\u20138.","DOI":"10.1097\/00000658-200104000-00010"},{"key":"key\n\t\t\t\t20171010171220_B116","doi-asserted-by":"crossref","unstructured":"Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients. Crit Care Med1997; 27: 1066\u201372.","DOI":"10.1097\/00003246-199906000-00019"},{"key":"key\n\t\t\t\t20171010171220_B117","doi-asserted-by":"crossref","unstructured":"Swoboda SM, Merz WG, Lipsetta PA. Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect2003; 4: 345\u201354.","DOI":"10.1089\/109629603322761409"},{"key":"key\n\t\t\t\t20171010171220_B118","doi-asserted-by":"crossref","unstructured":"Todd JC, O'Neal VG, Grady KP et al. Reduction of secondary mycotic infections in the trauma intensivie care unit with fluconazole. J Trauma1991; 31: 1722\u201327.","DOI":"10.1097\/00005373-199112000-00062"},{"key":"key\n\t\t\t\t20171010171220_B119","doi-asserted-by":"crossref","unstructured":"Jacobs S, Price Evans DA, Tariq M et al. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med2003; 31: 1938\u201346.","DOI":"10.1097\/01.CCM.0000074724.71242.88"},{"key":"key\n\t\t\t\t20171010171220_B120","doi-asserted-by":"crossref","unstructured":"Zervos EE, Fink GW, Norman JG et al. Fluconazole increases bactericidal activity of neutrophils through non-cytokine-mediated pathway. J Trauma1996; 41: 465\u201370.","DOI":"10.1097\/00005373-199609000-00013"},{"key":"key\n\t\t\t\t20171010171220_B121","doi-asserted-by":"crossref","unstructured":"Ables AZ, Blumer NA, Valainis GT et al. Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: a prospective, double-blind, randomised placebo-controlled trial. Infect Dis Clin Pract2000; 9: 169\u201375.","DOI":"10.1097\/00019048-200009040-00006"},{"key":"key\n\t\t\t\t20171010171220_B122","doi-asserted-by":"crossref","unstructured":"Kam LW, Lin JD. Management of systemic candidal infections in the intensive care unit. Am J Health Syst Pharm2002; 59: 33\u201341.","DOI":"10.1093\/ajhp\/59.1.33"},{"key":"key\n\t\t\t\t20171010171220_B123","doi-asserted-by":"crossref","unstructured":"Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg2000; 135: 160\u20135.","DOI":"10.1001\/archsurg.135.2.160"},{"key":"key\n\t\t\t\t20171010171220_B124","doi-asserted-by":"crossref","unstructured":"Tortorano AM, Caspani L, Rigoni AL et al. Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect2004; 57: 8\u201313.","DOI":"10.1016\/j.jhin.2004.01.017"},{"key":"key\n\t\t\t\t20171010171220_B125","doi-asserted-by":"crossref","unstructured":"Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis2003; 3: 772\u201385.","DOI":"10.1016\/S1473-3099(03)00831-4"},{"key":"key\n\t\t\t\t20171010171220_B126","doi-asserted-by":"crossref","unstructured":"Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis2003; 3: 685\u2013702.","DOI":"10.1016\/S1473-3099(03)00801-6"},{"key":"key\n\t\t\t\t20171010171220_B127","doi-asserted-by":"crossref","unstructured":"Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis1998; 27: 1291\u20134.","DOI":"10.1086\/515006"},{"key":"key\n\t\t\t\t20171010171220_B128","doi-asserted-by":"crossref","unstructured":"Powderly WG, Finkelstein D, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med1995; 332: 700\u20135.","DOI":"10.1056\/NEJM199503163321102"},{"key":"key\n\t\t\t\t20171010171220_B129","doi-asserted-by":"crossref","unstructured":"Leen CL, Dunbar EM, Ellis ME et al. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect1990; 21: 55\u201360.","DOI":"10.1016\/0163-4453(90)90646-P"},{"key":"key\n\t\t\t\t20171010171220_B130","doi-asserted-by":"crossref","unstructured":"Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med1991; 151: 2458\u201364.","DOI":"10.1001\/archinte.1991.00400120096018"},{"key":"key\n\t\t\t\t20171010171220_B131","doi-asserted-by":"crossref","unstructured":"Just-Nubling G, Gentschew G, Meissner K. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis1991; 10: 917\u201321.","DOI":"10.1007\/BF02005444"},{"key":"key\n\t\t\t\t20171010171220_B132","doi-asserted-by":"crossref","unstructured":"Marriott DJ, Jones PD, Hoy JF et al. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Aust1993; 158: 312\u201316.","DOI":"10.5694\/j.1326-5377.1993.tb121784.x"},{"key":"key\n\t\t\t\t20171010171220_B133","doi-asserted-by":"crossref","unstructured":"Schuman P, Capps L, Peng G et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med1997; 126: 689\u201396.","DOI":"10.7326\/0003-4819-126-9-199705010-00003"},{"key":"key\n\t\t\t\t20171010171220_B134","doi-asserted-by":"crossref","unstructured":"Havlir DV, Dube MP, McCutchan JA et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis1998; 27: 1369\u201375.","DOI":"10.1086\/515018"},{"key":"key\n\t\t\t\t20171010171220_B135","doi-asserted-by":"crossref","unstructured":"Pagani JL, Chave JP, Casjka C et al. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother2002; 50: 231\u201340.","DOI":"10.1093\/jac\/dkf101"},{"key":"key\n\t\t\t\t20171010171220_B136","doi-asserted-by":"crossref","unstructured":"Vazquez JA, Peng G, Sobel JD et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis2001; 33: 1069\u201375.","DOI":"10.1086\/322641"},{"key":"key\n\t\t\t\t20171010171220_B137","unstructured":"Delfraissy JF. Prise en charge th\u00e9rapeutique des patients infect\u00e9s pas le VIH. Rapport Delfraissy. Paris: Flammarion, 2004."},{"key":"key\n\t\t\t\t20171010171220_B138","doi-asserted-by":"crossref","unstructured":"De Pauw BE, Raemaekers JM, Donnelly JP et al. An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol1995; 70: 83\u20137.","DOI":"10.1007\/BF01834385"},{"key":"key\n\t\t\t\t20171010171220_B139","doi-asserted-by":"crossref","unstructured":"Anaissie EJ, Vartivarian SE, Abi-Said D et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med1996; 101: 170\u20136.","DOI":"10.1016\/S0002-9343(96)80072-6"},{"key":"key\n\t\t\t\t20171010171220_B140","doi-asserted-by":"crossref","unstructured":"Anaissie EJ, Darouiche RO, Abi-Said D et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis1996; 23: 964\u201372.","DOI":"10.1093\/clinids\/23.5.964"},{"key":"key\n\t\t\t\t20171010171220_B141","doi-asserted-by":"crossref","unstructured":"Myoken Y, Kyo T, Kohara T et al. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia. Clin Infect Dis2003; 36: 1496\u20137.","DOI":"10.1086\/374894"},{"key":"key\n\t\t\t\t20171010171220_B142","doi-asserted-by":"crossref","unstructured":"Anttila VJ, Farkkila M, Jansson SE et al. Diagnostic laparoscopy in patients with acute leukemia and suspected hepatic candidiasis. Eur J Clin Microbiol Infect Dis1997; 16: 637\u201343.","DOI":"10.1007\/BF01708552"},{"key":"key\n\t\t\t\t20171010171220_B143","doi-asserted-by":"crossref","unstructured":"Anaissie E, Bodey GP, Kantarjian H et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med1991; 91: 142\u201350.","DOI":"10.1016\/0002-9343(91)90006-J"},{"key":"key\n\t\t\t\t20171010171220_B144","doi-asserted-by":"crossref","unstructured":"Kauffman CA, Bradley SF, Ross SC et al. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med1991; 91: 137\u201341.","DOI":"10.1016\/0002-9343(91)90005-I"},{"key":"key\n\t\t\t\t20171010171220_B145","doi-asserted-by":"crossref","unstructured":"Kontoyiannis DP, Luna MA, Samuels BI et al. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am2000; 14: 721\u201339.","DOI":"10.1016\/S0891-5520(05)70128-8"},{"key":"key\n\t\t\t\t20171010171220_B146","doi-asserted-by":"crossref","unstructured":"Graninger W, Presteril E, Schneeweiss B et al. Treatment of Candida albicans fungaemia with fluconazole. J Infect1993; 26: 133\u201346.","DOI":"10.1016\/0163-4453(93)92761-K"},{"key":"key\n\t\t\t\t20171010171220_B147","doi-asserted-by":"crossref","unstructured":"Phillips P, Shafran S, Garber G et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis1997; 16: 337\u201345.","DOI":"10.1007\/BF01726360"},{"key":"key\n\t\t\t\t20171010171220_B148","doi-asserted-by":"crossref","unstructured":"Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med1994; 331: 1325\u201330.","DOI":"10.1056\/NEJM199411173312001"},{"key":"key\n\t\t\t\t20171010171220_B149","doi-asserted-by":"crossref","unstructured":"Abele-Horn M, Kopp A, Sternberg U et al. A randomized study comparing fluconazole with amphotericin B\/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection1996; 24: 426\u201332.","DOI":"10.1007\/BF01713042"},{"key":"key\n\t\t\t\t20171010171220_B150","doi-asserted-by":"crossref","unstructured":"Nguyen MH, Peacock JE Jr, Tanner DC et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med1995; 155: 2429\u201335.","DOI":"10.1001\/archinte.1995.00430220087009"},{"key":"key\n\t\t\t\t20171010171220_B151","doi-asserted-by":"crossref","unstructured":"Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis2003; 36: 1221\u20138.","DOI":"10.1086\/374850"},{"key":"key\n\t\t\t\t20171010171220_B152","doi-asserted-by":"crossref","unstructured":"Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med2002; 347: 2020\u20139.","DOI":"10.1056\/NEJMoa021585"},{"key":"key\n\t\t\t\t20171010171220_B153","doi-asserted-by":"crossref","unstructured":"Sugar AM, Saunders C, Diamond RD et al. Successful treatment of Candida osteomyelitis with fluconazole. A noncomparative study of two patients. Diagn Microbiol Infect Dis1990; 13: 517\u201320.","DOI":"10.1016\/0732-8893(90)90084-9"},{"key":"key\n\t\t\t\t20171010171220_B154","doi-asserted-by":"crossref","unstructured":"Tang C. Successful treatment of Candida albicans osteomyelitis with fluconazole. J Infect1993; 26: 89\u201392.","DOI":"10.1016\/0163-4453(93)97064-5"},{"key":"key\n\t\t\t\t20171010171220_B155","unstructured":"Lafont A, Olive A, Gelman M et al. Candida albicans spondylodiscitis and vertebral osteomyelitis in patients with intravenous heroin drug addiction. Report of 3 new cases. J Rheumatol1994; 21: 953\u20136."},{"key":"key\n\t\t\t\t20171010171220_B156","doi-asserted-by":"crossref","unstructured":"Hennequin C, Bouree P, Hiesse C et al. Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature. Clin Infect Dis1996; 23: 176\u20138.","DOI":"10.1093\/clinids\/23.1.176"},{"key":"key\n\t\t\t\t20171010171220_B157","doi-asserted-by":"crossref","unstructured":"Jonnalagadda S, Veerabagu MP, Rakela J et al. Candida albicans osteomyelitis in a liver transplant recipient: a case report and review of the literature. Transplantation1996; 62: 1182\u20134.","DOI":"10.1097\/00007890-199610270-00028"},{"key":"key\n\t\t\t\t20171010171220_B158","doi-asserted-by":"crossref","unstructured":"Rossel P, Schonheyder HC, Nielsen H. Fluconazole therapy in Candida albicans spondylodiscitis. Scand J Infect Dis1998; 30: 527\u201330.","DOI":"10.1080\/00365549850161601"},{"key":"key\n\t\t\t\t20171010171220_B159","doi-asserted-by":"crossref","unstructured":"Turner DL, Johnson SA, Rule SA. Successful treatment of candidal osteomyelitis with fluconazole following failure with liposomal amphotericin B. J Infect1999; 38: 51\u20133.","DOI":"10.1016\/S0163-4453(99)90032-4"},{"key":"key\n\t\t\t\t20171010171220_B160","doi-asserted-by":"crossref","unstructured":"El-Zaatari MM, Hulten K, Fares Y et al. Successful treatment of Candida albicans osteomyelitis of the spine with fluconazole and surgical debridement: case report. J Chemother2002; 14: 627\u201330.","DOI":"10.1179\/joc.2002.14.6.627"},{"key":"key\n\t\t\t\t20171010171220_B161","doi-asserted-by":"crossref","unstructured":"Seravalli L, Van Linthoudt D, Bernet C et al. Candida glabrata spinal osteomyelitis involving two contiguous lumbar vertebrae: a case report and review of the literature. Diagn Microbiol Infect Dis2003; 45: 137\u201341.","DOI":"10.1016\/S0732-8893(02)00497-2"},{"key":"key\n\t\t\t\t20171010171220_B162","doi-asserted-by":"crossref","unstructured":"Garbino J, Schnyder I, Lew DP et al. An unusual cause of vertebral osteomyelitis: Candida species. Scand J Infect Dis2003; 35: 288\u201391.","DOI":"10.1080\/00365540310000067"},{"key":"key\n\t\t\t\t20171010171220_B163","doi-asserted-by":"crossref","unstructured":"Tunkel AR, Thomas CY, Wispelwey B. Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature. Am J Med1993; 94: 100\u20133.","DOI":"10.1016\/0002-9343(93)90127-B"},{"key":"key\n\t\t\t\t20171010171220_B164","doi-asserted-by":"crossref","unstructured":"Cushing RD, Fulgenzi WR. Synovial fluid levels of fluconazole in a patient with Candida parapsilosis prosthetic joint infection who had an excellent clinical response. J Arthroplasty1997; 12: 950.","DOI":"10.1016\/S0883-5403(97)90166-2"},{"key":"key\n\t\t\t\t20171010171220_B165","doi-asserted-by":"crossref","unstructured":"Fukasawa N, Shirakura K. Candida arthritis after total knee arthroplasty\u2014a case of successful treatment without prosthesis removal. Acta Orthop Scand1997; 68: 306\u20137.","DOI":"10.3109\/17453679708996709"},{"key":"key\n\t\t\t\t20171010171220_B166","doi-asserted-by":"crossref","unstructured":"Lerch K, Kalteis T, Schubert T et al. Prosthetic joint infections with osteomyelitis due to Candida albicans. Mycoses2003; 46: 462\u20136.","DOI":"10.1046\/j.0933-7407.2003.00928.x"},{"key":"key\n\t\t\t\t20171010171220_B167","doi-asserted-by":"crossref","unstructured":"Clancy CJ, Nguyen MH, Morris AJ. Candidal mediastinitis: an emerging clinical entity. Clin Infect Dis1997; 25: 608\u201313.","DOI":"10.1086\/513770"},{"key":"key\n\t\t\t\t20171010171220_B168","doi-asserted-by":"crossref","unstructured":"Petrikkos G, Skiada A, Sabatakou H et al. Case report. Successful treatment of two cases of post-surgical sternal osteomyelitis, due to Candida krusei and Candida albicans, respectively, with high doses of triazoles (fluconazole, itraconazole). Mycoses2001; 44: 422\u20135.","DOI":"10.1046\/j.1439-0507.2001.00673.x"},{"key":"key\n\t\t\t\t20171010171220_B169","doi-asserted-by":"crossref","unstructured":"Weers-Pothoff G, Havermans JF, Kamphuis J et al. Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature. Infection1997; 25: 109\u201311.","DOI":"10.1007\/BF02113588"},{"key":"key\n\t\t\t\t20171010171220_B170","doi-asserted-by":"crossref","unstructured":"Laatikainen L, Tuominen M, von Dickhoff K. Treatment of endogenous fungal endophthalmitis with systemic fluconazole with or without vitrectomy. Am J Ophthalmol1992; 113: 205\u20137.","DOI":"10.1016\/S0002-9394(14)71537-5"},{"key":"key\n\t\t\t\t20171010171220_B171","doi-asserted-by":"crossref","unstructured":"Borne MJ, Elliott JH, O'Day DM. Ocular fluconazole treatment of Candida parapsilosis endophthalmitis after failed intravitreal amphotericin B. Arch Ophthalmol1993; 111: 1326\u20137.","DOI":"10.1001\/archopht.1993.01090100032019"},{"key":"key\n\t\t\t\t20171010171220_B172","doi-asserted-by":"crossref","unstructured":"Zarbin MA, Becker E, Witcher J et al. Treatment of presumed fungal endophthalmitis with oral fluconazole. Ophthalmic Surg Lasers1996; 27: 628\u201331.","DOI":"10.3928\/1542-8877-19960701-12"},{"key":"key\n\t\t\t\t20171010171220_B173","doi-asserted-by":"crossref","unstructured":"Wong VK, Tasman W, Eagle RC et al. Bilateral Candida parapsilosis endophthalmitis. Arch Ophthalmol1997; 115: 670\u20132.","DOI":"10.1001\/archopht.1997.01100150672022"},{"key":"key\n\t\t\t\t20171010171220_B174","doi-asserted-by":"crossref","unstructured":"Kauffman CA, Bradley SF, Vine AK. Candida endophthalmitis associated with intraocular lens implantation: efficacy of fluconazole therapy. Mycoses1993; 36: 13\u201317.","DOI":"10.1111\/j.1439-0507.1993.tb00681.x"},{"key":"key\n\t\t\t\t20171010171220_B175","doi-asserted-by":"crossref","unstructured":"del Palacio A, Cuetara MS, Ferro M et al. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses1993; 36: 193\u20139.","DOI":"10.1111\/j.1439-0507.1993.tb00749.x"},{"key":"key\n\t\t\t\t20171010171220_B176","doi-asserted-by":"crossref","unstructured":"Luttrull JK, Wan WL, Kubak BM et al. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol1995; 119: 477\u201381.","DOI":"10.1016\/S0002-9394(14)71234-6"},{"key":"key\n\t\t\t\t20171010171220_B177","doi-asserted-by":"crossref","unstructured":"Akler ME, Vellend H, McNeely DM et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis1995; 20: 657\u201364.","DOI":"10.1093\/clinids\/20.3.657"},{"key":"key\n\t\t\t\t20171010171220_B178","doi-asserted-by":"crossref","unstructured":"Christmas NJ, Smiddy WE. Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers1996; 27: 1012\u201318.","DOI":"10.3928\/1542-8877-19961201-07"},{"key":"key\n\t\t\t\t20171010171220_B179","doi-asserted-by":"crossref","unstructured":"Essman TF, Flynn HW, Smiddy WE et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers1997; 28: 185\u201394.","DOI":"10.3928\/1542-8877-19970301-03"},{"key":"key\n\t\t\t\t20171010171220_B180","doi-asserted-by":"crossref","unstructured":"Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis1998; 27: 1130\u20133.","DOI":"10.1086\/514972"},{"key":"key\n\t\t\t\t20171010171220_B181","doi-asserted-by":"crossref","unstructured":"Aleixo MJ, Caldeira L, Ferreira ML. Candida albicans meningitis: clinical case. J Infect2000 ; 40: 191\u20132.","DOI":"10.1016\/S0163-4453(00)80017-1"},{"key":"key\n\t\t\t\t20171010171220_B182","unstructured":"Inoue Y, Yozu R, Ueda T et al. A case report of Candida parapsilosis endocarditis. J Heart Valve Dis1998; 7: 240\u20132."},{"key":"key\n\t\t\t\t20171010171220_B183","doi-asserted-by":"crossref","unstructured":"Isalska BJ, Stanbridge TN. Fluconazole in the treatment of candidal prosthetic valve endocarditis. BMJ1988; 297: 178\u20139.","DOI":"10.1136\/bmj.297.6642.178"},{"key":"key\n\t\t\t\t20171010171220_B184","doi-asserted-by":"crossref","unstructured":"Martino P, Meloni G, Cassone A. Candidal endocarditis and treatment with fluconazole and granulocyte-macrophage colony-stimulating factor. Ann Intern Med1990; 112: 966\u20137.","DOI":"10.7326\/0003-4819-112-12-966_2"},{"key":"key\n\t\t\t\t20171010171220_B185","doi-asserted-by":"crossref","unstructured":"Roupie E, Darmon JY, Brochard L et al. Fluconazole therapy of candidal native valve endocarditis. Eur J Clin Microbiol Infect Dis1991; 10: 458\u20139.","DOI":"10.1007\/BF01968030"},{"key":"key\n\t\t\t\t20171010171220_B186","doi-asserted-by":"crossref","unstructured":"Hernandez JA, Gonzalez-Moreno M, Llibre JM et al. Candidal mitral endocarditis and long-term treatment with fluconazole in a patient with human immunodeficiency virus infection. Clin Infect Dis1992; 15: 1062\u20133.","DOI":"10.1093\/clind\/15.6.1062"},{"key":"key\n\t\t\t\t20171010171220_B187","doi-asserted-by":"crossref","unstructured":"Venditti M, De Bernardis F, Micozzi A, et al. Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis. Clin Infect Dis1992; 14: 422\u20136.","DOI":"10.1093\/clinids\/14.2.422"},{"key":"key\n\t\t\t\t20171010171220_B188","doi-asserted-by":"crossref","unstructured":"Wallbridge DR, McCartney AC, Richardson MD. Fluconazole in the treatment of Candida prosthetic valve endocarditis. Mycoses1993; 36: 259\u201361.","DOI":"10.1111\/j.1439-0507.1993.tb00761.x"},{"key":"key\n\t\t\t\t20171010171220_B189","unstructured":"Otaki M, Kitamura N. Candida prosthetic valve endocarditis. An autopsy review. Int Surg1993; 78: 252\u20133."},{"key":"key\n\t\t\t\t20171010171220_B190","doi-asserted-by":"crossref","unstructured":"Czwerwiec FS, Bilsker MS, Kamerman ML et al. Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. Am J Med1993; 94: 545\u20136.","DOI":"10.1016\/0002-9343(93)90092-4"},{"key":"key\n\t\t\t\t20171010171220_B191","doi-asserted-by":"crossref","unstructured":"Thakur RK, Skelcy KM, Kahn RN et al. Successful treatment of Candida prosthetic valve endocarditis with a combination of fluconazole and amphotericin B. Crit Care Med1994; 22: 712\u201314.","DOI":"10.1097\/00003246-199404000-00031"},{"key":"key\n\t\t\t\t20171010171220_B192","unstructured":"Cancelas JA, Lopez J, Cabezudo E et al. Native valve endocarditis due to Candida parapsilosis: a late complication after bone marrow transplantation-related fungemia. Bone Marrow Transplant1994; 13: 333\u20134."},{"key":"key\n\t\t\t\t20171010171220_B193","doi-asserted-by":"crossref","unstructured":"Zahid MA, Klotz SA, Hinthorn DR. Medical treatment of recurrent candidemia in a patient with probable Candida parapsilosis prosthetic valve endocarditis. Chest1994; 105: 1597\u20138.","DOI":"10.1378\/chest.105.5.1597"},{"key":"key\n\t\t\t\t20171010171220_B194","doi-asserted-by":"crossref","unstructured":"Wells CJ, Leech G, Lever AM et al. Treatment of native valve Candida endocarditis with fluconazole. J Infect1995; 31: 233\u20135.","DOI":"10.1016\/S0163-4453(95)80033-6"},{"key":"key\n\t\t\t\t20171010171220_B195","doi-asserted-by":"crossref","unstructured":"Gilbert HM, Peters ED, Lang SJ et al. Successful treatment of fungal prosthetic valve endocarditis: case report and review. Clin Infect Dis1996; 22: 348\u201354.","DOI":"10.1093\/clinids\/22.2.348"},{"key":"key\n\t\t\t\t20171010171220_B196","doi-asserted-by":"crossref","unstructured":"Nguyen MH, Nguyen ML, Yu VL et al. Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clin Infect Dis1996; 22: 262\u20137.","DOI":"10.1093\/clinids\/22.2.262"},{"key":"key\n\t\t\t\t20171010171220_B197","doi-asserted-by":"crossref","unstructured":"Lejko-Zupanc T, Kozelj M. A case of recurrent Candida parapsilosis prosthetic valve endocarditis: cure by medical treatment alone. J Infect1997; 35: 81\u20132.","DOI":"10.1016\/S0163-4453(97)91145-2"},{"key":"key\n\t\t\t\t20171010171220_B198","doi-asserted-by":"crossref","unstructured":"Joly V, Belmatoug N, Leperre A et al. Pacemaker endocarditis due to Candida albicans: case report and review. Clin Infect Dis1997; 25: 1359\u201362.","DOI":"10.1086\/516125"},{"key":"key\n\t\t\t\t20171010171220_B199","doi-asserted-by":"crossref","unstructured":"Rex JH, Walsh T, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis2000; 30: 662\u201378.","DOI":"10.1086\/313749"},{"key":"key\n\t\t\t\t20171010171220_B200","doi-asserted-by":"crossref","unstructured":"Baddour LM. Long-term suppressive therapy for Candida parapsilosis-induced prosthetic valve endocarditis. Mayo Clin Proc1995; 70: 773\u20135.","DOI":"10.4065\/70.8.773"},{"key":"key\n\t\t\t\t20171010171220_B201","doi-asserted-by":"crossref","unstructured":"Melgar GR, Nasser RM, Gordon SM. Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine1997; 76: 94\u2013103.","DOI":"10.1097\/00005792-199703000-00002"},{"key":"key\n\t\t\t\t20171010171220_B202","doi-asserted-by":"crossref","unstructured":"Dupont H, Paugam-Burtz C, Muller-Serieys C et al. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg2002; 137: 1341\u20136.","DOI":"10.1001\/archsurg.137.12.1341"},{"key":"key\n\t\t\t\t20171010171220_B203","doi-asserted-by":"crossref","unstructured":"Lee SC, Fung CP, Chen HY et al. Candida peritonitis due to peptic ulcer perforation: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B. Diagn Microbiol Infect Dis2002; 44: 23\u20137.","DOI":"10.1016\/S0732-8893(02)00419-4"},{"key":"key\n\t\t\t\t20171010171220_B204","doi-asserted-by":"crossref","unstructured":"Levine J, Bernard DB, Idelson BA et al. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent. Am J Med1989; 86: 825\u20137.","DOI":"10.1016\/0002-9343(89)90481-6"},{"key":"key\n\t\t\t\t20171010171220_B205","doi-asserted-by":"crossref","unstructured":"Michel C, Courdavault L, al Khayat R et al. Fungal peritonitis in patients on peritoneal dialysis. Am J Nephrol1994; 14: 113\u201320.","DOI":"10.1159\/000168699"},{"key":"key\n\t\t\t\t20171010171220_B206","doi-asserted-by":"crossref","unstructured":"Wang AY, Yu AW, Li PK et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis2000; 36: 1183\u201392.","DOI":"10.1053\/ajkd.2000.19833"},{"key":"key\n\t\t\t\t20171010171220_B207","doi-asserted-by":"crossref","unstructured":"Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis2003; 36: 14\u201318.","DOI":"10.1086\/344651"},{"key":"key\n\t\t\t\t20171010171220_B208","doi-asserted-by":"crossref","unstructured":"Kauffman CA, Vazquez JA, Sobel JD et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis2000, 30: 14\u201318.","DOI":"10.1086\/313583"},{"key":"key\n\t\t\t\t20171010171220_B209","doi-asserted-by":"crossref","unstructured":"Sobel JD, Kauffman CA, McKinsey D et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis2000; 30: 19\u201324.","DOI":"10.1086\/313580"},{"key":"key\n\t\t\t\t20171010171220_B210","doi-asserted-by":"crossref","unstructured":"Lundstrom T, Sobel J. Nosocomial candiduria: a review. Clin Infect Dis2001; 32: 1602\u20137.","DOI":"10.1086\/320531"},{"key":"key\n\t\t\t\t20171010171220_B211","doi-asserted-by":"crossref","unstructured":"Kaufman D, Boyle R, Hazen KC et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med2001; 345: 1660\u20136.","DOI":"10.1056\/NEJMoa010494"},{"key":"key\n\t\t\t\t20171010171220_B212","doi-asserted-by":"crossref","unstructured":"Kicklighter SD, Springer SC, Cox T et al. Fluconazole for the prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics2001; 107: 293\u20138.","DOI":"10.1542\/peds.107.2.293"},{"key":"key\n\t\t\t\t20171010171220_B213","doi-asserted-by":"crossref","unstructured":"McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev2004: CD003850.","DOI":"10.1002\/14651858.CD003850.pub2"},{"key":"key\n\t\t\t\t20171010171220_B214","unstructured":"Agarwal J, Bansal S, Malik GK et al. Trends in neonatal septicemia: emergence of non-albicans Candida. Indian Pediatr2004; 41: 712\u201315."},{"key":"key\n\t\t\t\t20171010171220_B215","doi-asserted-by":"crossref","unstructured":"Fasano C, O'Keefe J, Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis1994; 13: 351\u20134.","DOI":"10.1007\/BF01974619"},{"key":"key\n\t\t\t\t20171010171220_B216","doi-asserted-by":"crossref","unstructured":"Wainer S, Cooper PA, Gouws H et al. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J1997; 16: 763\u20137.","DOI":"10.1097\/00006454-199708000-00007"},{"key":"key\n\t\t\t\t20171010171220_B217","doi-asserted-by":"crossref","unstructured":"Huang YC, Lin TY, Lien RI et al. Fluconazole therapy in neonatal candidemia. Am J Perinatol2000; 17: 411\u201315.","DOI":"10.1055\/s-2000-13454"},{"key":"key\n\t\t\t\t20171010171220_B218","doi-asserted-by":"crossref","unstructured":"Huttova M, Hartmanova I, Kralinsky K et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr Infect Dis J1998; 17: 1012\u201315.","DOI":"10.1097\/00006454-199811000-00010"},{"key":"key\n\t\t\t\t20171010171220_B219","doi-asserted-by":"crossref","unstructured":"Gurpinar AN, Balkan E, Kilic N et al. Fluconazole treatment of neonates and infants with severe fungal infections. J Int Med Res1997; 25: 214\u201318.","DOI":"10.1177\/030006059702500408"},{"key":"key\n\t\t\t\t20171010171220_B220","doi-asserted-by":"crossref","unstructured":"Driessen M, Ellis JB, Muwazi F et al. The treatment of systemic candidiasis in neonates with oral fluconazole. Ann Trop Pediatr1997; 17: 263\u201371.","DOI":"10.1080\/02724936.1997.11747897"},{"key":"key\n\t\t\t\t20171010171220_B221","doi-asserted-by":"crossref","unstructured":"Driessen M, Ellis JB, Cooper PA et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J1997; 15: 1107\u201312.","DOI":"10.1097\/00006454-199612000-00011"},{"key":"key\n\t\t\t\t20171010171220_B222","doi-asserted-by":"crossref","unstructured":"Marr B, Gross S, Cunningham C et al. Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine. Clin Infect Dis1994; 19: 795\u20136.","DOI":"10.1093\/clinids\/19.4.795"},{"key":"key\n\t\t\t\t20171010171220_B223","doi-asserted-by":"crossref","unstructured":"Oleinik EM, Della-Latta P, Rinaldi MG et al. Candida lusitaniae osteomyelitis in a premature infant. Am J Perinatol1993; 10: 313\u201315.","DOI":"10.1055\/s-2007-994749"},{"key":"key\n\t\t\t\t20171010171220_B224","doi-asserted-by":"crossref","unstructured":"Mondal RK, Singhi SC, Chakrabarti A. Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr Crit Care Med2004; 5: 561\u20135.","DOI":"10.1097\/01.PCC.0000144712.29127.81"},{"key":"key\n\t\t\t\t20171010171220_B225","doi-asserted-by":"crossref","unstructured":"Viscoli C, Castagnola E, Fioredda F et al. Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother1991; 35: 365\u20137.","DOI":"10.1128\/AAC.35.2.365"},{"key":"key\n\t\t\t\t20171010171220_B226","unstructured":"Decruyenaere J, Colardyn F, Vogelaers D et al. Combined use of fluconazole and selective digestive decontamination in the prevention of fungal infection after adult liver transplantation. Transplant Proc1995; 27: 3515\u201316."},{"key":"key\n\t\t\t\t20171010171220_B227","doi-asserted-by":"crossref","unstructured":"Koh LP, Kurup A, Goh YT et al. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol2002; 71: 260\u20137.","DOI":"10.1002\/ajh.10234"},{"key":"key\n\t\t\t\t20171010171220_B228","unstructured":"Gluckman E, Esperou-Bourdeau H, Ribaud P et al. Comparaison entre le fluconazole et le k\u00e9toconazole pour la prophylaxie des infections fongiques chez les patients trait\u00e9s par greffe de moelle allog\u00e9nique. Cah Oncol1993; 2: 167\u20139."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/57\/3\/384\/2203119\/dki473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T11:40:42Z","timestamp":1627040442000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/57\/3\/384\/738005\/Fluconazole-for-the-management-of-invasive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,31]]},"references-count":228,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,1,31]]},"published-print":{"date-parts":[[2006,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki473","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,3]]},"published":{"date-parts":[[2006,1,31]]}}}